Degenerative Disc R&D Heats Up: Biorthex Evaluates Cervical Fusion Device
This article was originally published in The Gray Sheet
Executive Summary
Biorthex' recent IDE for the Actipore ACF places the Montreal-based firm with Medtronic and Synthes-Stratec in developing cervical implant approvals for the U.S. market
You may also be interested in...
Artificial Lumbar Disc Trial Results Could Make SpineCore Acquisition Target
SpineCore will begin a randomized, multi-site U.S. clinical trial for its FlexiCore intervertebral disc this month under a July 25 FDA investigational device exemption
Biorthex Anticipating Fourth-Quarter Roll-Out Of SpineCor Scoliosis Brace
Biorthex is planning a fourth-quarter U.S. launch of its SpineCor scoliosis brace, pending 510(k) clearance by FDA. Priced at approximately $1,000, the device will be positioned as an alternative and less restrictive treatment for early idiopathic scoliosis.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”